This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.

Pfizer raised its earnings outlook slightly when it reported second-quarter earnings on Aug. 5, 2025. Upcoming losses of ...

Now, it’s worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 182% for ...

PFE eyes Q2 earnings beat as strength in Vyndaqel and Padcev is expected to offset declines from Eliquis, Ibrance and Prevnar ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Merck is a strong and profitable pick meeting Benjamin Graham's criteria. Read more on why investors need to stay aware of ...

BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 21, Truist Securities initiated coverage of BBIO with a Buy rating and a ...

Below are 10 no-brainer energy stocks to buy now, with an explanation of which types of investors might want to buy them. Where to invest $1,000 right now?

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them.

Luno has launched the ability to purchase tokenised blue-chip stocks on its platform. Backed by actual stocks, this gives ...